Lunsumio and Polivy showed an 88% overall response rate in relapsed/refractory MCL patients, with high efficacy in high-risk subgroups. The combination therapy was well-tolerated, despite a high ...

Early ASH 2025 data suggest sonrotoclax is a promising therapy in MCL, supporting a broader shift toward chemo-free, combination-based strategies—particularly for patients with BTK ...

Approximately one-third of patients with relapsed or refractory mantle cell lymphoma (MCL) in this study treated with CAR T-cell therapy experienced disease progression, with a median progression time ...

Please provide your email address to receive an email when new articles are posted on . Historically, combined ACL and MCL injuries were often treated with open surgical approaches with much resultant ...